VORWARTS PHARMA
Live / Registered — Registered (as of 11 Nov 2025)
What this means for you
Registered since 11 Nov 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98403934
- Registration number
- 8024806
- Mark type
- Design + words
- Filed
- 13 Feb 2024
- Published for opposition
- 12 Nov 2024
- Registered
- 11 Nov 2025
- Attorney of record
- Diana Portna
Goods and services
- Class 005 — Pharmaceuticals: Acai powder dietary supplements; Acaricides; Adjuvants for medical purposes; Albumin dietary supplements; Alginate dietary supplements; Amino acids for medical purposes; Anaesthetics; Analgesics; Anthelmintics; Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antibiotics; Antiparasitic preparations; Antiseptics; Appetite suppressant pills; Bacterial preparations for medical and veterinary use; Bacteriological preparations for medical and veterinary use; Cardiovascular pharmaceuticals; Casein dietary supplements; Cellulose esters for pharmaceutical purposes; Charcoal for pharmaceutical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of erectile dysfunction, for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, for the treatment of diabetes, for the treatment of cardiovascular and cerebrovascular diseases, for the treatment of anaphylactic reactions;; Dietary supplements with a cosmetic effect; Digestives for pharmaceutical purposes; Enzyme dietary supplements; Enzyme preparations for medical purposes; Ferments for pharmaceutical purposes; Food supplements, namely, anti-oxidants; Glycerine for medical purposes; Haemoglobin; Herbal extracts, other than essential oils, for medical purposes; Infant formula; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Injectable pharmaceuticals for treatment of anaphylactic reactions; Lecithin dietary supplements; Medical preparations for slimming purposes; Medicated candies; Medicinal preparations for the treatment of erectile dysfunction, for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, for the treatment of diabetes, for the treatment of cardiovascular and cerebrovascular diseases, for the treatment of anaphylactic reactions; Mineral dietary supplements; Nutraceuticals for the treatment of erectile dysfunction, ocular disorders or diseases, bacteria-based diseases, diabetes, cardiovascular and cerebrovascular diseases, anaphylactic reactions; Nutraceuticals for use as a dietary supplement; Nutritional supplements; Ocular pharmaceuticals; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of bone fractures; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of rectile dysfunction, ocular disorders or diseases, bacteria-based diseases, diabetes, cardiovascular and cerebrovascular diseases, anaphylactic reactions; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Propolis dietary supplements; Propolis for pharmaceutical purposes; Protein dietary supplements; Vaginal washes for medical purposes; Vermifuges; Vitamin preparations; Wheat germ dietary supplements; Yeast dietary supplements; Yeast for pharmaceutical purposes
Owner
- Vorwarts Pharma SIA, Riga, LV
- Vorwarts Pharma SIA, Riga, LV
- Vorwarts Pharma SIA, Riga, LV
Prosecution history
- 11 Nov 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 11 Nov 2025 — REGISTERED-PRINCIPAL REGISTER
- 21 Oct 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 21 Oct 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 18 Oct 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 15 May 2025 — USE AMENDMENT FILED
- 18 Oct 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 15 May 2025 — TEAS STATEMENT OF USE RECEIVED
- 24 Dec 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 12 Nov 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 12 Nov 2024 — PUBLISHED FOR OPPOSITION
- 23 Oct 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 03 Oct 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 02 Oct 2024 — ASSIGNED TO EXAMINER
- 25 Jun 2024 — NOTICE OF DESIGN SEARCH CODE E-MAILED